HuniLife Biotechnology, Inc.
Quick facts
Phase 3 pipeline
- Lenalidomide and Dexamethasone · Oncology
Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: